BMS-986553 for Adults With Autoimmune Diseases That Have Not Responded to Treatment
Tests the safety of BMS-986553 in adults with hard-to-treat autoimmune diseases.
Plain-language title generated from the registry record
Registry title: A Study of BMS-986553 in Participants With Refractory Autoimmune Diseases
Key facts
- Where
- Berlin, Erlangen, Magdeburg, and Würzburg, GermanySee the 4 sites
- Phase
- Phase 1
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with a hard-to-treat autoimmune disease: lupus (SLE), inflammatory muscle disease (IIM), systemic sclerosis (SSc), rheumatoid arthritis (RA) or Sjögren's disease (SjD).
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- A confirmed diagnosis of SLE, IIM, SSc, RA or primary SjD that meets the named ACR/EULAR classification criteria. The study title calls the diseases refractory (not responding to treatment).
Main reasons for not taking part
- Having other systemic immune disorders
- Healthy volunteers cannot join
Read by machine on 9 November 2026.
Where in Germany
- BerlinBerlin, GermanyNo longer taking part
- ErlangenErlangen, GermanyNo longer taking part
- MagdeburgMagdeburg, GermanyNo longer taking part
- WürzburgWürzburg, GermanyNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Bristol-Myers Squibb
- Trial code
- NCT07873931
- Record updated
- 14 October 2026
- Original description
The purpose of this study is to evaluate the safety and tolerability of BMS-986553, CD19 in vivo Chimeric Antigen Receptor (CAR) T cells, in participants with refractory autoimmune diseases including systemic lupus erythematosus (SLE), idiopathic inflammatory myopathies (IIM), systemic sclerosis (SSc), rheumatoid arthritis (RA), and Sjögren's disease (SjD).Read full original descriptionShow less
A Phase 1, Multicenter, Open-Label Study of BMS-986553, CD19 In Vivo Chimeric Antigen Receptor (CAR) T Cells, in Participants With Refractory Autoimmune Diseases
The purpose of this study is to evaluate the safety and tolerability of BMS-986553, CD19 in vivo Chimeric Antigen Receptor (CAR) T cells, in participants with refractory autoimmune diseases including systemic lupus erythematosus (SLE), idiopathic inflammatory myopathies (IIM), systemic sclerosis (SSc), rheumatoid arthritis (RA), and Sjögren's disease (SjD).
Inclusion: SLE participants: Must have diagnosis of SLE defined as fulfilling the 2019 ACR/EULAR classification criteria of SLE; IIM participants: Must have diagnosis of IIM defined as fulfilling the 2017 ACR/EULAR classification criteria for probable or definite IIM; SSc participants: Must have diagnosis of SSc defined as fulfilling 2013 ACR/EULAR classification criteria for SSc; RA participants: Must have diagnosis of RA, defined as fulfilling 2010 ACR/EULAR criteria for RA; Primary SjD Participants: Must have diagnosis fulfilling the 2016 ACR/EULAR Classification Criteria.
Exclusion: Participants must not have other systemic immune disorders. Other protocol-defined Inclusion/Exclusion criteria apply.